# A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD

Study · id `cardio:ct-nct02547935` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02547935](<https://clinicaltrials.gov/study/NCT02547935>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02547935

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 459 participants.

## Technical summary

Registry record NCT02547935. Randomized; double masking; primary purpose treatment. Start 2015-09-21 (actual); primary completion 2018-05-18 (actual). Results posted on 2019-06-04.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 459 participants (enrolled count; ClinicalTrials.gov record NCT02547935, source copy `cardio:ctgov-nct02547935-2019-08-21`, retrieved 2026-10-26)
- Started: 2015-09-21 (actual) (ClinicalTrials.gov record NCT02547935, source copy `cardio:ctgov-nct02547935-2019-08-21`, retrieved 2026-10-26)
- Primary completion: 2018-05-18 (actual) (ClinicalTrials.gov record NCT02547935, source copy `cardio:ctgov-nct02547935-2019-08-21`, retrieved 2026-10-26)
- Completion: 2018-05-18 (actual) (ClinicalTrials.gov record NCT02547935, source copy `cardio:ctgov-nct02547935-2019-08-21`, retrieved 2026-10-26)
- Results first posted: 2019-06-04 (ClinicalTrials.gov record NCT02547935, source copy `cardio:ctgov-nct02547935-2019-08-21`, retrieved 2026-10-26)
- Countries: United States; Australia; Canada; Japan; Mexico; South Africa; South Korea; Spain; Taiwan (ClinicalTrials.gov record NCT02547935, source copy `cardio:ctgov-nct02547935-2019-08-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02547935-2019-08-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD
- Condition: Type 2 Diabetes Mellitus, CKD and Albuminuria
- Intervention (Drug): Dapagliflozin 10 mg
- Intervention (Drug): Saxagliptin 2.5 mg
- Intervention (Drug): Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial (`cardio:pubmed-30992195`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial (`cardio:pubmed-38017482`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 27e10bc65f5c445d9a456d78581d7ef7ca4e69204a3c7fc83c9d7e6b48b545c7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
